Takeda and Seattle Genetics reported positive results from a clinical trial of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma at the ASH meeting, showing that 75 percent of subjects in the study achieved an objective response. Seattle Genetics noted that following discussions with the FDA, the company plans to submit regulatory filings in the first quarter of 2011 to seek approval for both relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma. CEO Clay Siegall said the "goal would be to submit in the first quarter, have an accelerated review and be on the market in 2011."
Reference Articles
Seattle Genetics's experimental drug shrinks Hodgkin's tumors, study shows - (Bloomberg)
Seattle Genetics and Millennium report positive data from pivotal trial of brentuximab vedotin (SGN-35) in relapsed or refractory hodgkin lymphoma at ASH Annual Meeting - (Seattle Genetics)
Seattle Genetics, Millennium report groundbreaking results with drug for Hodgkin’s - (Xconomy)
Seattle Genetics to submit lymphoma drug to FDA - (Yahoo!News)
*Published in "First Word"
No comments:
Post a Comment